Posted by: APO | 17 April 2018

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

– Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years – Commitment includes expanding access to pediatric antimalarials and implementing capacity-building programs to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030 – New opinion research in Africa shows 2030 malaria elimination… Read more on


%d bloggers like this: